Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | VNN1 | O95497 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62554 | 0.87 | ABCB1 (0.47) | RAB9AABCB1VNN1ROCK2ROCK1 | |
| SCHEMBL62361 | 0.87 | ABCB1 (0.47) | RAB9AABCB1VNN1ROCK2ROCK1 | |
| SCHEMBL65150 | 0.87 | ABCB1 (0.49) | RAB9AABCB1VNN1ROCK2ROCK1 | |
| SCHEMBL64118 | 0.87 | KCNQ3 (0.52) | RAB9AABCB1ROCK2ROCK1NR3C2 | |
| SCHEMBL64290 | 0.87 | RAB9A (0.62) | RAB9AABCB1VNN1ROCK2ROCK1 | |
| SCHEMBL64528 | 0.85 | P4HTM (0.53) | ABCB1VNN1ROCK2ROCK1NR3C2 | |
| SCHEMBL64697 | 0.85 | ABCB1 (0.46) | RAB9AABCB1VNN1ROCK2ROCK1 | |
| SCHEMBL1853874 | 0.85 | ABCB1 (0.45) | RAB9AABCB1VNN1ROCK2ROCK1 | |
| SCHEMBL1856714 | 0.84 | ABCB1 (0.44) | RAB9AABCB1VNN1ROCK2ROCK1 | |
| SCHEMBL65051 | 0.84 | HDAC1 (0.44) | RAB9AABCB1VNN1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125748-B1 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2011-05-25 | — | — | EP | claimed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-20150299134-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-22 | — | — | US | disclosed |
| US-20140066455-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-03-06 | — | — | US | disclosed |
| US-8604022-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2013-12-10 | — | — | US | disclosed |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | ASTRAZENECA AB | 2012-05-24 | — | — | US | disclosed |
| US-8129391-B2 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-2125748-B1 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | ASTRAZENECA AB | 2010-10-28 | — | — | US | disclosed |
| US-7737149-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| EP-2125748-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | AstraZeneca AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | RAB9A 1091/4885CHEK1 2544/4885ABCB1 41/4885 |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | RAB9A 1957/4885CHEK1 1674/4885ABCB1 97/4885 |
| US-20140066455-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | RAB9A 701/4885CHEK1 1491/4885ABCB1 32/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | RAB9A 903/4885CHEK1 203/4885ABCB1 134/4885 |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | RAB9A 1957/4885CHEK1 1674/4885ABCB1 97/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | RAB9A 701/4885CHEK1 1491/4885ABCB1 32/4885 |
| US-20150299134-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | RAB9A 701/4885CHEK1 1491/4885ABCB1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.